Jamie Macdonald, Parexel
July 2, 2021 11:36 AM EDT
Deals
R&D

The CRO mad­ness con­tin­ues as Gold­man Sachs-backed buy­er group shells out $8.5B for Parex­el

Kyle Blankenship

The Covid-19 pan­dem­ic has kicked the con­tract re­search field in­to high gear, with a par­tic­u­lar fo­cus on de­cen­tral­ized tri­als as the re­search tool of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times